Abstract: The present invention relates to purified peptidomimetic macrocycles. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications.
Type:
Grant
Filed:
January 13, 2012
Date of Patent:
July 19, 2016
Assignee:
AILERON THERAPEUTICS, INC.
Inventors:
Huw M. Nash, Matthew Iadanza, Christopher Leitheiser, Noriyuki Kawahata
Abstract: The present disclosure provides synthesized peptides containing azetidine-2-carboxylic acid (Aze), methods for detecting antibodies to peptides containing Aze, and methods for diagnosing conditions associated with misincorporation of Aze into host proteins.
Type:
Grant
Filed:
December 23, 2013
Date of Patent:
May 31, 2016
Assignee:
The Board of Trustees of the Leland Stanford Junio
Abstract: The present invention relates to a product comprising at least two antibiofilm agents wherein at least one of the antibiofilm agents is an antimicrobial peptide. The second antibiofilm agent is cysteamine. There is also provided the use of the product in the treatment of a microbial infection.
Abstract: In order to provide a composition for treating, improving, or preventing pain, it has been found out that a metallothionein protein is expressed in a normal peripheral nerve, and that the expression is not observed in a peripheral nerve producing pain. Moreover, it has been found out that administering metallothionein to rats having neuropathic pain suppresses the pain in the rats.
Abstract: The present invention relates to the use, especially the cosmetic and/or therapeutic use, of the protein DJ-1, of polypeptides derived from this protein or of analogs thereof, of a nucleic acid sequence coding for such a polypeptide or of a modulator of the activity, stability or expression of such a polypeptide, especially for preventing and/or treating the signs of skin dryness. The invention also relates to the use of the protein DJ-1, of polypeptides derived from this protein or of analogs thereof or of a nucleic acid sequence coding for such a polypeptide, as a marker for evaluating the state of dryness of an epithelium.
Abstract: Techniques are disclosed for treating or reducing symptoms associated with abdominal dysfunction or ileus following surgery or other abdominal episode by treating the area with a combination of one or more protease, antibacterial compound, and inflammatory lipid mediator.
Type:
Grant
Filed:
October 3, 2011
Date of Patent:
March 29, 2016
Assignee:
The Regents of the University of California
Inventors:
Frank A. Delano, Geert W. Schmid-Schonbein, Darin Saltzman
Abstract: A targeting peptide that specifically binds to an IL13 receptor (e.g., wherein said targeting peptide is not an IL13 fragment) is described. The targeting peptide is optionally conjugated to at least one effector molecule. In some embodiments, the peptide specifically binds to the IL13R?2 protein.
Abstract: Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin active-site in reduced state and optionally further contains a reducing system.
Abstract: The invention relates to novel pharmaceutically-useful peptides, in particular cyclic peptides that are agonists of the AngII type 2 receptor (AT2 receptor). The invention further relates to the use of such peptides as medicaments, to pharmaceutical compositions containing them, and to their production.
Type:
Grant
Filed:
November 22, 2011
Date of Patent:
March 22, 2016
Assignee:
Lanthio Pep B.V.
Inventors:
Louwe De Vries, Sieger Adriaan Nelemans, Rick Rink, Antonius Jacobus Marinus Roks, Gert Nikolaas Moll
Abstract: The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3. The method includes a composition or combination comprising the multimeric antimicrobial peptides and at least one active pharmaceutical ingredient.
Type:
Grant
Filed:
November 26, 2013
Date of Patent:
December 29, 2015
Assignees:
Singapore Health Services Pte Ltd., Agency for Science, Technology and Research
Inventors:
Roger W. Beuerman, Shouping Liu, Jing Li, Lei Zhou, Chandra Shekhar Verma, Donald Tan
Abstract: The invention provides a method for preventing or treating a disease caused by an extracellular microorganism, said method comprising systemically administering to a subject in need thereof a prophylactically or therapeutically effective amount of a salicylic acid (SAL) or a SAL analog. The extracellular microorganism can be of the bacterial genus Staphylococcus, for example, Staphylococcus aureus. The extracellular microorganism can be a strain that is resistant to at least one antibiotic. The strain can be selected from the group consisting of methycillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA).
Type:
Grant
Filed:
March 28, 2014
Date of Patent:
December 8, 2015
Assignee:
LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER
Abstract: The present invention relates to purified peptidomimetic macrocycles. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications.
Type:
Grant
Filed:
September 22, 2009
Date of Patent:
December 8, 2015
Assignee:
AILERON THERAPEUTICS, INC.
Inventors:
Huw M. Nash, Matthew Iadanza, Christopher Leitheiser, Noriyuki Kawahata
Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
Abstract: Disclosed herein, in certain embodiments, is an HC•HA complex comprising hyaluronan and a heavy chain of I?I, wherein the transfer of the heavy chain of I?I is catalyzed by TSG-6. Further disclosed herein, in certain embodiments, is an HC•HA complex comprising hyaluronan and a heavy chain of I?I, wherein the transfer of the heavy chain of I?I is catalyzed by the TSG-6 like protein. Additionally, disclosed herein are methods of manufacturing said complex and methods of use thereof.
Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
Type:
Grant
Filed:
August 28, 2013
Date of Patent:
October 27, 2015
Assignee:
Shire Orphan Thereapies GmbH
Inventors:
Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Hellberg
Abstract: A method of promoting wound healing, treating fibrosis and/or promoting angiogenesis is provided. The method comprises administering to a subject in need thereof a therapeutically effective amount of a procollagen, thereby promoting wound healing, treating fibrosis and/or promoting angiogenesis in the subject.
Type:
Grant
Filed:
April 16, 2009
Date of Patent:
August 4, 2015
Assignee:
CollPlant Ltd.
Inventors:
Oded Shoseyov, Or Dgany, Daniel L. Siegel
Abstract: The present invention provides a benzazepine compound that can maintain for a long period of time the blood level of tolvaptan enabling to provide the desired pharmaceutical effects. The benzazepine compound of the present invention is represented by general formula (1) wherein R1 represents a —CO—(CH2)n—COR2 group (wherein n is an integer of 1 to 4, and R2 is (2-1) a hydroxy group; (2-2) a lower alkoxy group optionally substituted with a hydroxy group, a lower alkanoyl group, a lower alkanoyloxy group, a lower alkoxycarbonyloxy group, a cycloalkyloxycarbonyloxy group, or 5 -methyl-2-oxo-1,3-dioxol-4-yl; or (2-3) an amino group optionally substituted with a hydroxy-lower alkyl group), or the like.
Abstract: The present invention relates to a method for assessing a subject's risk of having a cardiovascular disease comprising the step of measuring the level of IF1 in a body fluid sample obtained from said subject wherein the level of EF1 is negatively correlated with the risk of said subject of having cardiovascular disease.
Type:
Grant
Filed:
January 25, 2012
Date of Patent:
June 9, 2015
Assignees:
Institut National de la Santé et de la Recherche Médicale (INSERM), CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
Abstract: The present disclosure relates to preterm infant formulas comprising lutein, lycopene, and beta-carotene, and the use of the preterm infant formulas to modulate inflammation, such as skin inflammation, in preterm infants. Also disclosed are methods of modulating the level of C-reactive protein in a preterm infant using preterm infant formulas comprising mixtures of carotenoids.